

Table S1. Demographic and clinical data for secondary and subsequent *B. pseudomallei* isolates.

Individuals		
	<i>n</i> patients	11
	<i>n</i> individuals with co-morbidities	11
	Age range	16-74 years
	Gender	54.5% F, 45.5% M
Isolate collection site		
	Lung	6
	Blood	3
	Skin and soft tissue	2
	Bone/joint	1
	Urine	1
Isolate total		
	<i>n</i>	13

Table S2. Cefiderocol *in vitro* minimum inhibitory concentrations (mg/L) and disc diffusion range (mm) for clinical *B. pseudomallei* isolates collected from individuals over time. Subsequent isolates are shaded green, red or yellow to show a decrease, increase or no change in MIC from the original isolate, respectively.

Original Isolate	CEF MIC	Disc Zone	Date Collected	Subsequent Isolate/s	CEF MIC	Disc Zone	Date Collected
C4	8	14	2006	C5	8	20	2009
				C6	8	18	2012
				C7	8	19	2014
T63	0.125	38	1996	C15	8	18	2010
C50	4	29	2000	C52	4	30	2000
C28	≤0.03	39	2012	C29	0.06	37	2017
T64	≤0.03	40	1999	T118	0.125	43	2002
C18	0.125	40	2011	C20	0.06	42	2011
C87	≤0.03	40	2014	C88	≤0.03	41	2014
C37	0.125	39	2015	C38	0.06	41	2016
C174	0.06	42	2017	C175	≤0.03	40	2017
C106	≤0.03	41	2015	C107	≤0.03	41	2015
T19	≤0.03	37	1997	T43	0.5	43	1999
<i>n</i> = 11	MIC <sub>90</sub> 4	14-41	1996-2017	<i>n</i> = 13	MIC <sub>90</sub> 8	18-43	1999-2017